We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Danimer Scientific Inc | NYSE:DNMR | NYSE | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
-0.0354 | -4.63% | 0.729 | 0.77899 | 0.6901 | 0.7562 | 816,283 | 22:38:01 |
-- Results In-Line with March 20 Preannouncement --
-- Issues FY24 Guidance with Expectation for Accelerating Sales Growth --
Danimer Scientific, Inc. (NYSE: DNMR) (“Danimer” or the “Company”), a leading next generation bioplastics company focused on the development and production of biodegradable materials, announced today financial results for its fourth quarter and full year, ended December 31, 2023.
Stephen E. Croskrey, Chairman and Chief Executive Officer of Danimer, commented, “While 2023 was a challenging year for the Company, we are greatly encouraged by the successes we had and we believe we remain well ahead of the competition in both deep understanding of the biodegradable plastics industry and the available production capacity to meet current and future customers’ needs. We are excited for the year ahead and focused on leveraging our global market-leadership position in PHA-based materials to drive value to our customers, partners and shareholders.
Croskrey continued, “We maintain a strong belief that we will significantly grow our business in 2024 as we continue to fulfill our mission to eliminate plastic pollution from petroleum-based plastics through the adoption and use of PHA-based materials as biodegradable alternatives in a variety of end markets. Our recently completed equity offering transaction enhances our operational liquidity runway and should enable us to support this expected growth.”
Fourth Quarter 2023 Financial Highlights:
Full Year 2023 Financial Highlights:
Capital Structure
At December 31, 2023, the Company reported total debt outstanding of $382.8 million, which included approximately $45.7 million dollars of low-interest New Markets Tax Credit loans that the Company expects will be forgiven beginning in 2026.
On March 20, 2024, we executed an equity offering which provided the Company with over $13 million in additional liquidity. This event improves the Company’s liquidity position and enables it to maintain strategic and operational flexibility as it executes its growth strategy. The Company noted that the effect of this transaction is not reflected in its December 31, 2023, financial statements.
Outlook
Michael Hajost, Danimer’s Chief Financial Officer, commented, “We are intently focused on revenue growth, which we expect to accelerate during the second half of 2024. As a result, we expect improvement in operating margins and operating cash flow as we move through the year.
For the full year 2024, the Company today provided the following guidance:
Webcast, Conference Call and 10-K Filing
The Company will host a webcast and conference call today, Thursday, March 28, 2024, at 4:30 p.m. Eastern time to review fourth quarter and full-year 2023 results, discuss recent events and conduct a question-and-answer session. The live webcast of the conference call can be accessed on the Investor Relations section of the Company’s website at https://ir.danimerscientific.com. For those unable to access the webcast, the conference call will be accessible domestically or internationally, by dialing 1-888-886-7786 or 1-416-764-8658, respectively. Upon dialing in, please request to join the Danimer Scientific Fourth Quarter 2023 Earnings Conference Call. The archived webcast will be available for replay on the Company's website after the call.
About Danimer Scientific
Danimer is a pioneer in creating more sustainable, more natural ways to make plastic products. For more than a decade, its renewable and sustainable biopolymers have helped create plastic products that are biodegradable and compostable and return to nature instead of polluting our lands and waters. Danimer’s technology can be found in a vast array of plastic end products that people use every day. Applications for its biopolymers include additives, aqueous coatings, fibers, filaments, films and injection-molded articles, among others. Danimer holds more than 480 granted patents and pending patent applications in more than 20 countries for a range of manufacturing processes and biopolymer formulations. For more information, visit https://danimerscientific.com.
Forward‐Looking Statements
Please note that in this press release we may use words such as “appears,” “anticipates,” “believes,” “plans,” “expects,” “intends,” “future,” and similar expressions which constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, statements regarding our expectations for the full year 2024 capital expenditures, Adjusted EBITDA and cash balances. Forward-looking statements are made based on our expectations and beliefs concerning future events impacting the Company and therefore involve a number of risks and uncertainties. We caution that forward-looking statements are not guarantees and that actual results could differ materially from those expressed or implied in the forward-looking statements. Potential risks and uncertainties that could cause the actual results of operations or financial condition of the Company to differ materially from those expressed or implied by forward-looking statements in this release include, but are not limited to, the overall level of consumer demand on our products; general economic conditions and other factors affecting consumer confidence, preferences, and behavior; disruption and volatility in the global currency, capital, and credit markets; the financial strength of the Company's customers; the Company's ability to implement its business strategy, including, but not limited to, its ability to expand its production facilities and plants to meet customer demand for its products and the timing thereof; risks relating to the uncertainty of the projected financial information with respect to the Company; the ability of the Company to execute and integrate acquisitions; changes in governmental regulation, legislation or public opinion relating to our products; the Company’s exposure to product liability or product warranty claims and other loss contingencies; disruptions and other impacts to the Company’s business, as a result of the COVID-19 global pandemic and government actions and restrictive measures implemented in response; stability of the Company’s manufacturing facilities and suppliers, as well as consumer demand for our products, in light of disease epidemics and health-related concerns such as the COVID-19 global pandemic; the impact on our business, operations and financial results from the ongoing conflict in Ukraine; the impact that global climate change trends may have on the Company and its suppliers and customers; the Company's ability to protect patents, trademarks and other intellectual property rights; any breaches of, or interruptions in, our information systems; the ability of our information technology systems or information security systems to operate effectively, including as a result of security breaches, viruses, hackers, malware, natural disasters, vendor business interruptions or other causes; our ability to properly maintain, protect, repair or upgrade our information technology systems or information security systems, or problems with our transitioning to upgraded or replacement systems; the impact of adverse publicity about the Company and/or its brands, including without limitation, through social media or in connection with brand damaging events and/or public perception; fluctuations in the price, availability and quality of raw materials and contracted products as well as foreign currency fluctuations; our ability to utilize potential net operating loss carryforwards; and changes in tax laws and liabilities, tariffs, legal, regulatory, political and economic risks. More information on potential factors that could affect the Company's financial results is included from time to time in the Company's public reports filed with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. All forward-looking statements included in this press release are based upon information available to the Company as of the date of this press release, and speak only as of the date hereof. We assume no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release.
Danimer Scientific, Inc.
Condensed Consolidated Balance Sheets
December 31,
December 31,
(in thousands, except share and per share data)2023
2022
Assets: Current assets: Cash and cash equivalents$
59,170
$
62,792
Accounts receivable, net
15,227
17,989
Other receivables, net
652
1,635
Inventories, net
25,270
32,743
Prepaid expenses and other current assets
4,714
5,225
Contract assets, net
3,005
4,687
Total current assets
108,038
125,071
Property, plant and equipment, net
445,153
453,949
Intangible assets, net
77,790
80,941
Right-of-use assets
19,160
19,028
Leverage loans receivable
31,446
31,446
Restricted cash
14,334
1,609
Other assets
2,210
226
Total assets
$
698,131
$
712,270
Liabilities and Stockholders' Equity: Current liabilities: Accounts payable
$
5,292
$
14,977
Accrued liabilities
4,726
5,001
Unearned revenue and contract liabilities
1,000
-
Current portion of lease liability
3,337
3,337
Current portion of long-term debt, net
1,368
1,972
Total current liabilities
15,723
25,287
Long-term lease liability, net
21,927
22,114
Long-term debt, net
381,436
286,398
Deferred income taxes
-
200
Other long-term liabilities
1,025
659
Total liabilities
$
420,111
$
334,658
Stockholders' equity: Common stock, $0.0001 par value; 200,000,000 shares authorized: 102,832,103 and 101,804,454 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively
$
10
$
10
Additional paid-in capital
732,131
676,250
Accumulated deficit
(454,121
)
(298,648
)
Total stockholders’ equity
278,020
377,612
Total liabilities and stockholders’ equity
$
698,131
$
712,270
Danimer Scientific, Inc.
Condensed Consolidated Statements of Operations
Years Ended December 31,
Years Ended December 31,
(in thousands, except share and per share data)
2023
2022
2023
2022
Revenue: Products
$
10,476
$
14,530
$
44,200
$
48,420
Services
469
794
2,484
4,798
Total revenue
10,945
15,324
46,684
53,218
Costs and expenses: Cost of revenue
17,317
18,026
73,644
63,632
Selling, general and administrative
16,885
19,547
68,983
81,589
Research and development
7,575
7,470
29,242
31,939
Loss on sale of assets
12
-
246
1
Impairment of long-lived assets
188
-
188
63,491
Total costs and expenses
41,977
45,043
172,303
240,652
Loss from operations
(31,032
)
(29,719
)
(125,619
)
(187,434
)
Nonoperating income (expense) Gain on remeasurement of private warrants
108
752
207
9,366
Interest, net
(8,509
)
474
(29,641
)
(1,723
)
Loss on loan extinguishment
-
-
(102
)
(1,500
)
Other, net
1
399
1
723
Total nonoperating income (expense):
(8,400
)
1,625
(29,535
)
6,866
Loss before income taxes
(39,432
)
(28,094
)
(155,154
)
(180,568
)
Income taxes
(2
)
43
(319
)
810
Net loss
$
(39,434
)
$
(28,051
)
$
(155,473
)
$
(179,758
)
Basic net loss per share$
(0.39
)
$
(0.28
)
$
(1.52
)
$
(1.78
)
Weighted average shares outstanding
102,144,873
101,397,811
102,001,812
101,095,341
Danimer Scientific, Inc.
Condensed Consolidated Statements of Cash Flows
Years Ended
December 31,
(in thousands)
2023
2022
Cash flows from operating activities: Net loss
$
(155,473
)
$
(179,758
)
Adjustments to reconcile net loss to net cash used in operating activities: Impairment of long-lived assets
188
63,491
Stock-based compensation
56,035
56,958
Depreciation and amortization
29,377
20,453
Amortization of debt issuance costs
8,990
2,104
Accounts receivable reserves
(1,422
)
1,904
Inventory reserves
949
101
Loss on extinguishment of debt
102
1,500
Contract asset reserve
-
1,216
Gain on remeasurement of private warrants
(207
)
(9,366
)
Deferred income taxes
(199
)
(814
)
Amortization of right-of-use assets and lease liability
(319
)
(367
)
Loss on disposal of assets
246
-
Other
967
62
Changes in operating assets and liabilities, net of effects of acquisition: Accounts receivable
4,184
(3,056
)
Other receivables
595
2,513
Inventories, net
6,481
(11,170
)
Prepaid expenses and other current assets
2,599
2,662
Contract assets
(1,011
)
(1,853
)
Other assets
(119
)
(479
)
Accounts payable
(635
)
(1,565
)
Accrued liabilities
604
(5,969
)
Other long-term liabilities
(196
)
(190
)
Unearned revenue and contract liabilities
1,000
(214
)
Net cash used in operating activities
(47,264
)
(61,837
)
Cash flows from investing activities: Purchases of property, plant and equipment and intangible assets
(27,685
)
(164,486
)
Investment in leverage loans receivable related to NMTC financing
-
(18,037
)
Acquisition of Novomer, net of cash acquired
-
(14
)
Proceeds from sales of property, plant and equipment
22
55
Net cash used in investing activities
(27,663
)
(182,482
)
Cash flows from financing activities: Proceeds from long-term debt
130,000
24,700
Cash paid for debt issuance costs
(33,296
)
(1,591
)
Principal payments on long-term debt
(13,030
)
(1,504
)
Proceeds from employee stock purchase plan
281
377
Proceeds from issuance of common stock, net of issuance costs
225
(236
)
Proceeds from exercise of stock options
-
215
Employee taxes related to stock-based compensation
(150
)
(154
)
Cost related to warrants
-
(55
)
Net cash provided by financing activities
84,030
21,752
Net increase (decrease) in cash and cash equivalents and restricted cash
9,103
(222,567
)
Cash and cash equivalents and restricted cash-beginning of period
64,401
286,968
Cash and cash equivalents and restricted cash-end of period
$
73,504
$
64,401
Non-GAAP Financial Measures
This press release includes the non-GAAP financial measures “Adjusted EBITDA”, “Adjusted gross profit” and "Adjusted gross margin". Danimer management views these metrics as a useful way to look at the performance of its operations between periods and to exclude decisions on capital investment and financing that might otherwise impact the review of profitability of the business based on present market conditions.
Adjusted EBITDA is defined as net income or loss plus net interest expense, income taxes, depreciation and amortization, as adjusted to add back certain charges or gains that Danimer may record each period such as remeasurement of private warrants, stock-based compensation expense, as well as non-recurring charges such as (i) asset disposal gains or losses as well as other significant gains or losses such as debt extinguishments and impairment of goodwill; (ii) legal settlements; or (iii) other discrete non-recurring items. Danimer believes these items are not considered an indicator of ongoing performance. Adjusted EBITDA is not a measure of performance defined in accordance with GAAP. The measure is used as a supplement to GAAP results in evaluating certain aspects of Danimer’s business, as described below.
Adjusted gross profit is defined as gross profit plus depreciation, stock-based compensation and other nonrecurring items.
Adjusted gross margin is defined as adjusted gross profit divided by total revenue.
Danimer believes that each of Adjusted EBITDA, Adjusted gross profit and Adjusted gross margin is useful to investors in evaluating the Company’s performance because each measure considers the performance of the Company’s operations, excluding decisions made with respect to capital investment, financing and other non-recurring charges as outlined in the preceding paragraph. Danimer believes these non-GAAP metrics offer additional financial information that, when coupled with the GAAP results and the reconciliation to GAAP results, provides a more complete understanding of its results of operations and the factors and trends affecting its business.
Adjusted EBITDA, Adjusted gross profit and Adjusted gross margin should not be considered as an alternative to net income or loss as an indicator of its performance or as alternatives to any other measure prescribed by GAAP as there are limitations to using such non-GAAP measures. Although Danimer believes that Adjusted EBITDA, Adjusted gross profit and Adjusted gross margin may enhance an evaluation of its operating performance based on recent revenue generation and product/overhead cost control because it excludes the impact of prior decisions made about capital investment, financing and other expenses, (i) other companies in Danimer’s industry may define Adjusted EBITDA, Adjusted gross profit and Adjusted gross margin differently than Danimer does and, as a result, they may not be comparable to similarly titled measures used by other companies in its industry, and (ii) Adjusted EBITDA, Adjusted gross profit and Adjusted gross margin exclude certain financial information that some may consider important in evaluating Danimer’s performance.
Danimer compensates for these limitations by providing disclosure of the differences between Adjusted EBITDA, Adjusted gross profit and Adjusted gross margin and GAAP results, including providing a reconciliation to GAAP results, to enable investors to perform their own analysis of Danimer’s operating results. Because GAAP financial measures on a forward-looking basis are not accessible, and reconciling information is not available without unreasonable effort, reconciliations to GAAP financial measures are not provided for forward-looking non-GAAP measures. For the same reasons, the Company is unable to address the probable significance of the unavailable information, which could be material to future results.
Danimer Scientific, Inc.
Reconciliation of Adjusted EBITDA to Net Loss (Unaudited)
Three Months Ended December 31,
Twelve Months Ended December 31,
2023
2022
2023
2022
(in thousands) Net loss$ (39,434)
$ (28,051)
$ (155,473)
$ (179,758)
Stock-based compensation12,906
14,218
55,839
56,768
Interest, net8,509
(474)
29,641
1,723
Depreciation and amortization7,372
7,281
29,377
20,453
Gain on remeasurement of private warrants(108)
(752)
(207)
(9,366)
Income taxes2
(43)
319
(810)
Litigation and other legal related84
146
207
2,082
Inventory reserve-
(495)
-
-
Loss on extinguishment of royalty agreement-
-
549
-
Strategic reorganization and related-
-
410
-
Loss on sale of assets-
-
246
1
Loss on loan extinguishment-
-
102
1,500
Impairment of goodwill-
-
-
62,663
Public company transition costs-
-
-
481
Other, net-
(399)
-
(723)
Adjusted EBITDA$ (10,669)
$ (8,569)
$ (38,990)
$ (44,986)
Reconciliation of Adjusted Gross Profit to Gross Profit (Unaudited)
Three Months Ended December 31,
Twelve Months Ended December 31,
2023
2022
2023
2022
(in thousands) Total revenue
$
10,945
$
15,324
$
46,684
$
53,218
Cost of revenue
17,317
18,026
73,644
63,632
Gross profit
(6,372
)
(2,702
)
(26,960
)
(10,414
)
Depreciation
5,153
5,161
20,386
12,249
Inventory reserve
-
(495
)
-
-
Loss on sale of assets
-
-
77
-
Stock-based compensation
2
-
10
60
Adjusted gross profit
$
(1,217
)
$
1,964
$
(6,487
)
$
1,895
Adjusted gross margin
-11.1
%
12.8
%
-13.9
%
3.6
%
View source version on businesswire.com: https://www.businesswire.com/news/home/20240328566875/en/
Investors Blake Chamblee Phone: 770-337-6570 ir@danimer.com
Media Richard Ivey Phone: 229-254-7688 rivey@danimer.com
1 Year Danimer Scientific Chart |
1 Month Danimer Scientific Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions